|Sertraline||Selective serotonin reuptake inhibitor|
Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole. In July 2017, it was in preregistration in Japan for the treatment of MDD. However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.
- "Aripiprazole/sertraline - Otsuka Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
- Kamdijima K, Kimura M, Kuwahara K, Kitayama Y, Tadori Y (August 2018). "Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder". Psychiatry and Clinical Neurosciences. 72 (8): 591–601. doi:10.1111/pcn.12663. PMID 29660207. S2CID 4958169.
- "Aripiprazole/sertraline - Otsuka Pharmaceutical - AdisInsight". adisinsight.springer.com.